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Anti-tumorigenic gene therapy offers many benefits over than conventional therapy i.e., 
chemotherapy or radiotherapy including less toxic side effects, rapid delivery and more 
sensitive compared to target-based drugs. Anti-tumorigenic agents alone were not 
proven to be effective in promoting the delay or regression of tumor mass in vivo due to 
low therapeutic gene transfer efficiency and the formation of new blood vessels in 
tumors. In addition, the blood vessels are one of the major factors that reduce the 
effectiveness of anti-tumorigenic agents. Consequently, a new therapeutic approach that 
combined both anti-tumorigenic and anti-angiogenic agents was established and proven 
to provide superior and beneficial synergistic effect. In the present study, a complete 
open reading frame (ORF) encoding endostatin protein was RNA extracted from a 
Balb/c mice liver tissue and transcribed into cDNA. The gene was then cloned into 
TOPO vector prior to a retroviral vector, pMSCVneo. Upon cloning and sequencing of 
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the full length of the gene, it was revealed that the complete ORF contained 550 
nucleotides, by which the size similar to that of established endostatin. While, anti-
tumorigenic gene; VP3 was obtained from previous study (generous gift from Professor 
Mohd Azmi Mohd Lila) and verified by PCR approaches. The PCR amplification and 
restriction endonuclease analysis showed that the gene product was convenient and 
similar to the expected size. The gene obtained was also 98% homology to that the 
references strain, Cux-1 by DNA sequencing analysis. Both recombinant constructs 
were transfected into PT67 cells and the transiently produced virus used to treat Balb/c 
mice with established colon tumors. The method of treatments was given in either as 
single modality or combined treatment with standardized of tumor size in each mice 
group. Here, we also revealed a viral delivery vehicle named 'retroviral vector’ to deliver 
the both anti-tumorigenic and anti-angiogenic agents into the tumor mass to achieve the 
effects of apoptosis. Furthermore, the retroviral-mediated gene therapies also showed no 
signs of adverse effect. Based on PCR approaches, the recombinant retrovirus particles 
were disseminated into the bloodstream and finally presented in various tissues but only 
expressed their therapeutic genes in tumors. As a result, the risk of undesirable 
characteristics of cancer gene therapy could be avoided in non-target tissues. The 
differential activities of VP3 and endostatin were investigated by the use of the 
immunohistochemistry analysis such as PCNA and vWF. The apoptosis activities upon 
expression of VP3 and endostatin were further studied by quantifying and identifying 
biochemical changes and number of affected cells due to apoptosis. Upon TUNEL and 
DNA fragmentation assays, typical apoptotic patterns were observed, to include 
formation of apoptotic bodies and visible DNA ladders, as early as 48 hours after 
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treatments. Since necrotic cells could be stained positively by TUNEL, a flow cytometry 
assay was developed for identifying and quantifying dead or dying cells in mode of cell 
death. The apoptosis percentage including early and late apoptotic quadrants showed 
that the combined tumor treatment was higher than VP3 and endostatin only. The effect 
of VP3 and endostatin protein expression in tumor and vital organ tissues were also 
confirmed upon examination by inverted microscopy analysis with H&E-stained 
sections. In addition, upon electron microscopic examination, typical morphological 
apoptotic features were observed including intact membranes and organelles, cell 
blebbing as well as condensed nuclear membranes in single- and combined-treated 
tumors not in other vital organ tissues. Interestingly, based on these constructive 
findings the combined treatment noted better responses in tumor bearing mice rather 
than single treatments. In conclusion, this study showed that the combined approach was 
more promising, effective and good governance on delay tumor growth and inducing 
apoptosis than introducing VP3 or endostatin alone. The combination treatment also 
offers potential benefits in control of tumorigenesis, and thus deserves further research 
as a preferred approach in cancer gene therapy. 
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Terapi gen anti-tumorigenic menawarkan banyak manfaat lebih dari terapi konvensional 
iaitu kemoterapi, atau radioterapi termasuk kesan sampingan yang kurang toksik, 
penghantaran cepat dan lebih sensitif berbanding dengan ubat sasaran yang 
berpusat. Agen anti-tumorigenic saja tidak terbukti berkesan dalam mempromosikan 
kelewatan atau regresi massa tumor in vivo berhubung dengan kecekapan pemindahan 
gen terapeutik yang rendah dan pembentukan pembuluh darah baru pada tumor. Selain 
itu, pembuluh darah merupakan salah satu faktor utama yang mengurangkan 
keberkesanan agen anti-tumorigenic. Akibatnya, pendekatan terapi baru yang 
digabungkan baik agen anti-tumorigenic dan anti-angiogenik didirikan dan terbukti 
memberikan kesan sinergis unggul dan bermanfaat. Dalam kajian ini, suatu rangka baca 
terbuka lengkap (ORF) encoding protein endostatin adalah RNA diekstraksi dari RNA 
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hati mencit Balb/c dan ditranskripsi menjadi cDNA. Gen ini kemudian diklon ke vektor 
TOPO sebelum vektor retroviral, pMSCVneo. Setelah pengklonan dan sekuensing 
panjang penuh gen, terungkap bahawa ORF lengkap mengandungi 550 nukleotida, di 
mana saiz serupa dengan endostatin ditetapkan. Sementara, gen anti-tumorigenic; VP3 
diperolehi daripada kajian sebelumnya (hadiah yang murah hati dari Profesor Mohd 
Azmi Mohd Lila) dan disahkan oleh pendekatan PCR. Amplifikasi PCR dan analisis 
sekatan endonuklease menunjukkan bahawa produk gen nyaman dan serupa dengan saiz 
yang diharapkan. Gen diperolehi juga 98 homologi% untuk bahawa strain rujukan, Cux-
1 dengan analisis DNA sekuensing. Kedua-dua rekombinan pembinaan tersebut 
transfected ke PT67 sel dan virus transiently yang dihasilkan digunakan untuk 
mengubati tikus Balb/c dengan tumor usus besar yang ditetapkan. 
Kaedah perlakuan diberikan dalam baik sebagai modalitas tunggalatau kombinasi perlak
uan dengan standard saiz tumor pada setiapkumpulan tikus. Di sini, kita juga 
mendedahkan sebuah kenderaan penghantaran virus bernama 'vektor retroviral untuk 
memberikan yang baik agen anti-tumorigenic dan anti-angiogenik ke dalam massa 
tumor untuk mencapai kesan-kesan apoptosis. Selanjutnya, gen terapi retroviral-
dimediasi juga tidak menunjukkan tanda-tanda kesan yang merugikan. Berdasarkan 
pendekatan PCR, zarah retrovirus rekombinan disebarkan ke dalam aliran darah dan 
akhirnya dihidangkan dalam pelbagai rangkaian tetapi hanya menyatakan gen terapeutik 
mereka pada tumor. Akibatnya, risiko ciri-ciri yang tidak diingini dari terapi kanser gen 
boleh dielakkan dalam rangkaian non-target. Kegiatan pembezaan dari beberapa VP3 
dan endostatin diteliti dengan menggunakan analisis imunohistokimia seperti PCNA dan 
vWF. Kegiatan apoptosis ini atas ekspresi VP3 dan endostatin yang melanjutkan 
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pengajian dengan mengukur dan mengenalpasti perubahan biokimia dan jumlah sel yang 
terkena kesan akibat apoptosis. Setelah Túnel dan ujian fragmentasi DNA, apoptosis 
pola khas diamati, untuk memasukkan pembentukan badan apoptosis dan tangga DNA 
terlihat, pada awal 48 jam selepas rawatan. Kerana sel nekrotik boleh diwarnai secara 
positif oleh TUNEL, alat ujian flow cytometry dibangunkan untuk pengenalan dan 
kuantifikasi mati atau sekarat sel dalam mod kematian sel. Peratus apoptosis termasuk 
kuadran apoptosis awal dan akhir menunjukkan bahawa kombinasi perlakuan tumor 
lebih tinggi dari VP3 dan endostatin saja. Pengaruh endostatin VP3 dan ekspresi protein 
pada rangkaian tumor dan organ vital juga disahkan pada pemeriksaan dengan analisa 
mikroskop inverted dengan H & E-bernoda.Selain itu, pada pemeriksaan mikroskopik 
elektron, ciri khas morfologi apoptosis yang diamati termasuk selaput utuh dan organel, 
blebbing sel serta selaput nuklear berlawan pada tumor tunggal dan gabungan yang 
dirawat tidak dalam rangkaian organ vital lain. Menariknya, berdasarkan penemuan 
konstruktif kombinasi perlakuan mencatat respon lebih baik pada tikus bantalan tumor 
daripada perlakuan tunggal. Sebagai kesimpulan, kajian ini menunjukkan bahawa 
pendekatan gabungan lebih menjanjikan, berkesan dan pemerintahan yang baik terhadap 
pertumbuhan tumor dan menunda apoptosis inducing dari memperkenalkan VP3 atau 
endostatin saja. Kombinasi perlakuan juga menawarkan potensi manfaat mengendalikan 
tumorigenesis, dan dengan demikian layak penelitian lebih lanjut sebagai pendekatan 
yang lebih disukai dalam terapi kanser gen. 
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